Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R43/R44)

Funding Opportunity Number: RFA-HL-15-027 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.838Eligible Applicants Small businessesAgency Name: HHS-NIH11Closing Date: Nov 09, 2016Award Ceiling: Expected Number of Awards: Creation Date: Dec 03, 2014Funding Opportunity Description: This program will support the commercial development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful SBIR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF lung disease.
Source: Grants.gov - Category: Research Tags: Health Source Type: funding